CO2022015205A2 - Procesos para la preparación de un inhibidor de cinasa - Google Patents

Procesos para la preparación de un inhibidor de cinasa

Info

Publication number
CO2022015205A2
CO2022015205A2 CONC2022/0015205A CO2022015205A CO2022015205A2 CO 2022015205 A2 CO2022015205 A2 CO 2022015205A2 CO 2022015205 A CO2022015205 A CO 2022015205A CO 2022015205 A2 CO2022015205 A2 CO 2022015205A2
Authority
CO
Colombia
Prior art keywords
processes
preparation
compound
kinase inhibitor
synthetic preparation
Prior art date
Application number
CONC2022/0015205A
Other languages
English (en)
Spanish (es)
Inventor
Frenel Demorin
Khalid Shah
Sagar Shakya
Yong Wang
Wei Xu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CO2022015205A2 publication Critical patent/CO2022015205A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2022/0015205A 2020-04-30 2022-10-26 Procesos para la preparación de un inhibidor de cinasa CO2022015205A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063017739P 2020-04-30 2020-04-30
PCT/US2021/030035 WO2021222673A1 (en) 2020-04-30 2021-04-30 Processes for the preparation of a kinase inhibitor

Publications (1)

Publication Number Publication Date
CO2022015205A2 true CO2022015205A2 (es) 2022-10-31

Family

ID=76076455

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0015205A CO2022015205A2 (es) 2020-04-30 2022-10-26 Procesos para la preparación de un inhibidor de cinasa

Country Status (27)

Country Link
US (1) US12497367B2 (cg-RX-API-DMAC7.html)
EP (1) EP4143169B1 (cg-RX-API-DMAC7.html)
JP (2) JP7728795B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230005190A (cg-RX-API-DMAC7.html)
CN (2) CN115461328B (cg-RX-API-DMAC7.html)
AU (1) AU2021263474A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021712A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176042A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003008A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022015205A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220551A (cg-RX-API-DMAC7.html)
DK (1) DK4143169T3 (cg-RX-API-DMAC7.html)
FI (1) FI4143169T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20267875B (cg-RX-API-DMAC7.html)
HR (1) HRP20260608T1 (cg-RX-API-DMAC7.html)
IL (2) IL297684B2 (cg-RX-API-DMAC7.html)
LT (1) LT4143169T (cg-RX-API-DMAC7.html)
MA (1) MA59466B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022013528A (cg-RX-API-DMAC7.html)
PE (1) PE20230110A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552821A1 (cg-RX-API-DMAC7.html)
PT (1) PT4143169T (cg-RX-API-DMAC7.html)
RS (1) RS68116B1 (cg-RX-API-DMAC7.html)
SI (1) SI4143169T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600219T1 (cg-RX-API-DMAC7.html)
TW (1) TWI887405B (cg-RX-API-DMAC7.html)
WO (1) WO2021222673A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1154105A (zh) 1994-06-08 1997-07-09 H·隆德贝克有限公司 4-芳基-1-(二氢化茚甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、-四氢吡啶或哌嗪类化合物
ZA954689B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
SMP200900002B (it) 2006-06-12 2010-01-19 Novartis Ag Sali di n-idrossi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]ammino]metil]fenil]-2e-2-propenammide
CN101466672B (zh) 2006-06-12 2012-05-16 诺瓦提斯公司 N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的盐
CA2743416A1 (en) * 2008-11-13 2010-05-20 Exelixis Inc. Methods of preparing quinoline derivatives
TW201920110A (zh) * 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
WO2012009722A1 (en) * 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
PL2768796T3 (pl) 2011-10-20 2020-05-18 Exelixis, Inc. Sposób wytwarzania pochodnych chinoliny
EA033834B1 (ru) 2014-07-31 2019-11-29 Exelixis Inc Способ получения кабозантиниба, меченного фтором-18, и его аналогов
AU2019212800B2 (en) 2018-01-26 2024-05-23 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
SG11202006945PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Also Published As

Publication number Publication date
IL324105A (en) 2025-12-01
CN115461328A (zh) 2022-12-09
JP7728795B2 (ja) 2025-08-25
TW202208335A (zh) 2022-03-01
BR112022021712A2 (pt) 2022-12-06
IL297684A (en) 2022-12-01
MX2022013528A (es) 2022-11-16
JP2025128388A (ja) 2025-09-02
SMT202600219T1 (it) 2026-07-16
AU2021263474A1 (en) 2022-11-17
KR20230005190A (ko) 2023-01-09
PH12022552821A1 (en) 2024-02-12
EP4143169A1 (en) 2023-03-08
IL297684B2 (en) 2026-07-01
US12497367B2 (en) 2025-12-16
HRP20260608T1 (hr) 2026-06-05
DK4143169T3 (en) 2026-06-08
CN121591655A (zh) 2026-03-03
CR20220551A (es) 2022-12-07
LT4143169T (lt) 2026-07-10
EP4143169B1 (en) 2026-04-15
GEP20267875B (en) 2026-03-25
TWI887405B (zh) 2025-06-21
PE20230110A1 (es) 2023-01-25
US20230192619A1 (en) 2023-06-22
CN115461328B (zh) 2025-11-07
CA3176042A1 (en) 2021-11-04
FI4143169T3 (fi) 2026-06-08
MA59466B1 (fr) 2026-05-26
PT4143169T (pt) 2026-05-21
RS68116B1 (sr) 2026-06-30
SI4143169T1 (sl) 2026-07-31
JP2023524692A (ja) 2023-06-13
CL2022003008A1 (es) 2023-06-23
WO2021222673A1 (en) 2021-11-04
IL297684B1 (en) 2026-03-01

Similar Documents

Publication Publication Date Title
CO2024001367A2 (es) Compuestos antivirales
ECSP22057865A (es) Inhibidores de formas mutantes de egfr
AR121226A1 (es) Compuestos y usos de estos
AR116604A1 (es) Inhibidores de kras g12c
AR126251A1 (es) Inhibidores de cdk2
AR107694A1 (es) Heteroarilos inhibidores de pad4
CL2022003008A1 (es) Procesos para la preparación de un inhibidor de cinasa
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
MX2023015245A (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2.
CO2021003391A2 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
CO2021014210A2 (es) Compuestos de pirrol
CO2021017202A2 (es) Compuestos tricíclicos
PE20231308A1 (es) Proceso e intermedios para preparar un inhibidor de jak1
MX2025007935A (es) Nuevos inhibidores reversibles de dpp1 y usos de estos
MX2024011179A (es) Compuestos multiciclicos
AR126196A1 (es) Proceso para preparar inhibidores de egfr
CL2024001298A1 (es) Compuestos de cd73
AR116951A1 (es) Sales cristalinas de un inhibidor de calicreína plasmática
DOP2025000009A (es) Inhibidores de acc novedosos
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo
AR127561A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
MX2024010402A (es) Inhibidores de proteinas de union a emopamilo y usos de estos
AR132761A1 (es) Compuesto inhibidor de la quinasa inducible por sal y composición farmacéutica que lo incluye
AR122372A1 (es) Compuestos y usos de estos
AR132987A1 (es) Compuestos para el tratamiento de trastornos neurológicos